
Eden Biologics Anticipates Initiation of Global Phase 3 in 2021 H2 for Its Denosumab Biosimilar
Eden Biologics today announced completion of enrollment for Phase 1 PK Clinical Trial of Eden's lead product candidate EB1001, a Denosumab biosimilar. HSINCHU, TAIWAN, February 25, 2021 /EINPresswire.com/ -- Eden Biologics, Inc., a global …